
AbbVie Inc.

ABBV (AbbVie Inc.) trades at 0.0x EV/Revenue — attractively valued for a healthcare & pharma company with best-in-class gross margins (84%) and mature growth profile. The business is highly profitable at 46% EBIT margins.
Companies in the top quartile for ESG metrics have outperformed the bottom quartile by 2.1% annually over the past decade.
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.
AbbVie is a global biopharmaceutical company that develops and commercializes advanced therapies for some of the world's most complex diseases. They focus primarily on immunology (like rheumatoid arthritis and Crohn's disease), oncology, neuroscience, and eye care, serving patients worldwide through innovative medicines. The company generates revenue by discovering, developing, and selling prescription drugs, with Humira (for autoimmune diseases) historically being their flagship product.
AbbVie is navigating the "Humira cliff" by rapidly scaling newer immunology drugs Skyrizi and Rinvoq, which combined grew over 50% year-over-year recently. The company's oncology portfolio, led by Imbruvica, represents a significant growth opportunity in the expanding cancer therapeutics market. Management expects the newer drug portfolio to more than offset Humira declines by 2025-2026.
AbbVie maintains industry-leading margins with gross margins typically above 80% and operating margins in the mid-30s range, reflecting the high-margin nature of patent-protected pharmaceuticals. The company generates substantial free cash flow conversion, typically 85-90% of net income, enabling consistent capital returns to shareholders. While margins may face near-term pressure from Humira erosion, the high-margin profile of replacement drugs should support long-term profitability.
AbbVie competes with pharmaceutical giants like Johnson & Johnson, Roche, and Pfizer in immunology and oncology markets. Their key differentiator lies in deep expertise in immunology and a strong track record of developing best-in-class treatments for autoimmune diseases. The company's extensive clinical development capabilities and established relationships with specialists create meaningful barriers to entry in their core therapeutic areas.
Recent quarters have shown the transition strategy taking hold, with Skyrizi and Rinvoq posting strong growth rates that are beginning to offset Humira declines in the U.S. The market has responded positively to pipeline updates and regulatory approvals expanding the addressable market for key growth drivers. Management confidence in achieving growth inflection points has improved investor sentiment around the post-Humira outlook.
Analysts are generally cautiously optimistic about AbbVie's diversification strategy, with most viewing the stock as a "show me" story requiring continued execution on new drug launches. Consensus expectations center around achieving revenue growth inflection by 2025-2026 as newer products scale. The main debate focuses on the timeline and magnitude of the transition, with some analysts more bullish on the durability of the immunology franchise.
AbbVie is a high-quality pharmaceutical company in the midst of its most critical transition, moving from Humira dependence to a diversified growth portfolio—success here will determine whether it remains a dividend aristocrat or faces years of declining returns.
Pre-generated investor questions answered by Claude Opus. Available in the Atlas AI tab.








| '25E | '26E | '27E | '28E | |
|---|---|---|---|---|
| Revenue | — | $67.1B | $72.6B | $77.9B |
| Growth | — | +8% | +7% | |
| EBITDA | — | $25.3B | $27.4B | $29.4B |
| Growth | — | +8% | +7% | |
| EPS (PF) | — | $14.57 | $16.19 | $17.87 |
| Growth | — |
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
Buy Or Fear AbbVie Stock At $210?
Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions
TrumpRx lists many medicines at prices higher than paid in UK
Big drugmakers must face US overcharge claims on medications for low-income patients
| +11% |
| +10% |